ISSN 1470-3947 (print)
ISSN 1479-6848 (online)

Searchable abstracts of presentations at key conferences in endocrinology

Published by BioScientifica
Endocrine Abstracts (2010) 22 P412 
|

Long-term outcome of 65 patients with metastatic differentiated thyroid carcinoma

Marta Dieguez, Edelmiro Menendez, Cecilia Sanchez, Javier Aller, Pedro Boix, Elias Delgado, Antonio Lavilla, Joaquin Pertierra & Antonio Rabal

Author affiliations

Aim: To assess survival rate and prognosis factors in a group of 65 patients with distant metastases from differentiated thyroid carcinoma.

Methods: Patients with metastatic differentiated thyroid carcinoma (MDTC) were retrospectively identified from the database of a single institution (1975–2008). Disease-specific survival (DSS) was analyzed by the Kaplan-Meier method.

Results: A total of 65 patients with MDTC were identified. The median follow-up was 90 months (range 3–328). Metastatic lesions were treated with radioactive iodine (77%), radiotherapy (18%), surgical resection (17%) and chemotherapy (3%). Following RECIS criteria, after treatment 70% of metastases progressed, 14% remained stable, 8% had a partial response and 9% had a complete response.

The overall survival rate was 59.5 months (CI 67–122). Disease-specific survival (DSS) was 39% at 5 years and 26% at 10 years.

Patients with micronodular pulmonary metastases and isolated bone metastases had significant longer DSS than patients with other type of metastases: 71% versus 25% at 5 years and 50% versus 16% at 10 years, respectively (P < 0.05).

Aged <45 years and iodine-avid metastases were also associated with better outcome.

No difference was observed for sex, TNM stage and time of diagnosis of metastases.

Conclusions: The current study, as well as others, suggests that MDTC may have a long-term survival.

Despite of treatment most metastases progress.

Age, site and extension of metastases and radioiodine uptake are the strongest prognosis factors.

This Issue/Conference

Article tools

My recent searches